Quest Diagnostics Inc Stock Price, News & Analysis

Quest Diagnostics recently supported a community COVID-19 testing event in Newark, NJ, as part of its Quest for Health Equity (Q4HE) initiative. This program, established in 2020, aims to address health disparities exacerbated by the pandemic, particularly among marginalized groups. Q4HE focuses on providing essential resources through education, engagement, empowerment, and access. Key strategies include COVID-19 testing and vaccinations, funding programs to tackle health inequities, and partnering with organizations to drive lasting change. The initiative underscores Quest's commitment to improving health outcomes for underserved communities.

Agilent Technologies (NYSE: A) has entered into a strategic agreement with Quest Diagnostics (NYSE: DGX) to facilitate access to the ctDx FIRST liquid biopsy next-generation sequencing test for advanced non-small cell lung cancer (NSCLC) patients in the U.S. This FDA-approved test will provide healthcare providers with a minimally invasive option to determine if patients could benefit from KRAZATI™ treatment. The collaboration aims to enhance the implementation of precision medicine in oncology, allowing healthcare providers to electronically order the test through Quest’s platform and utilize its extensive patient network.

Quest Diagnostics (NYSE: DGX) will announce its fourth quarter and full year 2022 financial results on February 2, 2023, prior to market opening. A conference call detailing these results will begin at 8:30 a.m. ET on the same day. Participants can dial in at 888-455-0391 (U.S. and Canada) or 773-756-0467 (international) with the passcode '7895081'. The earnings release and a live webcast will be available on www.QuestDiagnostics.com/investor. A replay of the call will be accessible from 10:30 a.m. ET on February 2 until midnight ET on February 16, 2023.

Quest Diagnostics, in a recent statement by Ruth Clements, highlighted the achievements of the Quest for Health Equity (Q4HE) program on its one-year anniversary. The initiative aims to reduce health disparities in underserved communities by enhancing access to diagnostic testing and educational resources. Clements noted the importance of ongoing collaboration with local and national partners to foster long-term health equity. Additionally, she emphasized the critical role Quest has played during the COVID-19 pandemic, particularly in supporting low-income and minority populations with testing and information. The commitment to addressing health inequities continues to be a priority for Quest Diagnostics.

On January 17, 2023, Quest Diagnostics (NYSE: DGX) announced plans for Pack Health to nearly double its headquarters in Birmingham, Alabama, creating at least 200 new full-time jobs. This expansion, supported by state and local economic incentives, is expected to generate an estimated $27 million in economic impact over the next 20 years. The new facility will enhance Pack Health's capabilities in providing digital health coaching and chronic condition management, vital for improving patient outcomes. This marks a year since Quest's acquisition of Pack Health, emphasizing its role in connecting diagnostic insights to actionable health improvements.

Quest Diagnostics has partnered with the American Heart Association (AHA) to address significant health disparities affecting Native Americans, particularly in heart disease, stroke, and diabetes. Since 2021, the Quest Diagnostics Foundation has funded AHA initiatives at Federally Qualified Health Centers (FQHCs) across six states, aiming to provide essential resources for hypertension and COVID-19.

The AHA's programs, supported by a Quest grant, focus on delivering effective high blood pressure resources to under-resourced communities severely impacted by the pandemic. This collaboration aims to improve health outcomes in multiple indigenous health centers.

Quest Diagnostics has awarded a grant to ConferMED, enhancing access to specialty care for underserved communities. The funding supports ConferMED's eConsult platform, connecting primary care providers in five U.S. regions with specialists. This initiative aims to address health inequities by providing virtual consultations at Federally Qualified Health Centers (FQHCs), impacting over 475,000 patients. The grant covers the full implementation cost and two years of services, improving chronic disease outcomes and reducing unnecessary hospital visits.

Quest Diagnostics announced partnerships aimed at facilitating safe participation in recreational activities post-COVID-19 pandemic. Key initiatives include acting as the sole on-site testing provider for the historic Boston Marathon, partnering with Carnival and Royal Caribbean for pre-cruise COVID-19 testing, and managing testing at the BNP Paribas Tennis Open. These efforts underscore Quest's commitment to health and safety during public events, helping to streamline testing procedures across various sectors.